Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396214 · ClinicalTrials.gov registry record · Phase 3
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
NCT00396214 is a Phase 3 study that was terminated before completion, run by Solvay Pharmaceuticals. The registered enrollment target is 83 participants.
The verdict
NCT00396214, a Phase 3 study, was terminated before completion, sponsored by Solvay Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
Interventions
- DRUG Quetiapine
- DRUG Bifeprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00396214
The ClinicalTrials.gov registry entry for NCT00396214 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quetiapine is the first listed.
NCT00396214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00396214 about?
NCT00396214 is a clinical study titled "Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients". The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
What is the current status of trial NCT00396214?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2007-04. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00396214?
The interventions under investigation include: Quetiapine (DRUG), Bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00396214?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.